
JAK vs TNF Inhibitors Show No Elevated CV Event Risk in RA
TOPLINE: Patients with rheumatoid arthritis (RA) treated with Janus kinase (JAK) inhibitors showed no increased incidence of major adverse cardiovascular events (MACEs) compared with those treated with tumour necrosis factor (TNF) inhibitors or biologic …